Related Experiment Video
Updated: Mar 12, 2026
08:51
Mammary Epithelial Transplant Procedure
Published on: June 10, 2010
31.9K
Deciphering Pro-Lymphangiogenic Programs during Mammary Involution and Postpartum Breast Cancer
Virginia F Borges1, Alan M Elder1, Traci R Lyons1
1Young Women's Breast Cancer Translational Program, University of Colorado Cancer Center, Aurora, CO, USA; Department of Medicine, Division of Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
Frontiers in Oncology
|November 18, 2016
Summary
Postpartum breast cancer, diagnosed within 5 years of childbirth, significantly increases metastasis and mortality risk in young women. Studying postpartum mammary lymphangiogenesis may reveal new therapeutic targets.
Area of Science:
- Oncology
- Reproductive Biology
Background:
- Postpartum breast cancer (PPC) is a distinct subtype in women diagnosed during or within 5 years of pregnancy.
- PPC is associated with a nearly twofold increased risk of metastasis and death compared to nulliparous women.
- Nearly half of breast cancers in women under 45 are classified as PPC, highlighting its public health significance.
Approach:
- Investigating preclinical mouse models of PPC reveals increased tumor cell aggressiveness during postpartum mammary gland involution.
- Examining the role of involution, a period of lymphatic remodeling, in PPC progression.
- Analyzing human PPC for high peritumor lymphatic vessel density (LVD) and lymph node metastasis.
Key Points:
- Postpartum mammary gland involution is linked to increased breast tumor cell aggressiveness.
- Lymphatic vessel density (LVD) is significantly elevated around postpartum tumors.
- Increased LVD correlates with a higher incidence of lymph node metastasis in PPC.
Conclusions:
- Understanding the biological mechanisms of postpartum mammary lymphangiogenesis is crucial.
- Investigating the tumor microenvironment in PPC may uncover novel therapeutic strategies.
- Targeted interventions based on PPC biology could benefit young women diagnosed with this aggressive cancer subtype.
